PTEN Antibody — Decoding Tumor Suppressor Inactivation and Guiding Precision Cancer Therapy

PTEN is one of the most critical tumor suppressor genes after p53. Its inactivation is closely associated with the occurrence, development, treatment response, and prognosis of many malignant tumors. PTEN antibodies serve as key tools for detecting PTEN expression and localization, supporting mechanistic research and clinical precision therapy.

1. Core Role of PTEN in Tumor Suppression
Encodes a dual‑specificity phosphatase; located on chromosome 10q23.3.
Mainly inactivated by deletion, mutation, or methylation.
Drives tumorigenesis in glioblastoma, prostate, breast, endometrial, lung, and other cancers.

2. Major Signaling Pathways Regulated by PTEN

Pathway	Regulatory Effect
PI3K/AKT pathway	Dephosphorylates PIP3 to inhibit AKT activation, suppressing proliferation and promoting apoptosis.
MAPK/ERK pathway	Negatively regulates Ras–ERK signaling to block excessive cell growth.
FAK pathway	Inhibits cell adhesion, migration, and EMT, thereby suppressing invasion and metastasis.

 

3. PTEN Regulation of the Cell Cycle
Induces G1‑phase arrest by upregulating p21, p27, and p57.
Nuclear–cytoplasmic localization determines functional activity.
Loss of nuclear PTEN indicates functional inactivation.

4. Value of PTEN Antibodies in Precision Therapy
IHC detection: Evaluates PTEN expression level and localization in tumor tissues.
PI3K/AKT/mTOR inhibitor guidance: PTEN‑loss patients may benefit from targeted pathway inhibitors.
Immunotherapy prediction: PTEN loss correlates with resistance to anti–PD‑1/PD‑L1 therapy.
Combined therapy: PTEN status helps design combinations of targeted drugs and immunotherapy.

5. PTEN Antibody Product from ANT BIO PTE. LTD.
PTEN Recombinant Rabbit mAb (Cat. No.: S0B2105)
High specificity & sensitivity; validated for IHC, WB, IF.
Recombinant monoclonal design ensures stable performance and minimal batch variation.
Clear nuclear/cytoplasmic staining; low background.
Ideal for tumor pathology, prognostic evaluation, and pathway research.

Conclusion
PTEN is a central tumor suppressor that controls multiple oncogenic signaling pathways. PTEN antibodies enable reliable detection of PTEN loss or dysfunction, helping stratify patients, predict therapeutic response, and guide precision cancer treatment.